Pierre Fabre secures Italian distribution rights for Noventure’s Aprotecol
pharmafile | July 17, 2017 | News story | Sales and Marketing | Aprotecol, Noventure, Pierre Fabre, biotech, colic, drugs, healthcare, pharma, pharmacuetical
Noventure has allied with Pierre Fabre Pharma Italy in a partnership which will see the latter distribute the Spanish start-up’s paediatric intestinal treatment Aprotecol in Italy.
Aprotecol is available as an oily suspension administered via medical device, designed to prevent and treat intestinal colic, meteorism and aerophagy – ailments that frequently occur in infants and children. Colic itself affects one in five children under three months and can become a drain on health services when a worried parent takes their child to seek professional aid. Aprotecol treats the condition by delivering a film-forming agent to reinforce the mucosal barrier in the intestines and prevents increased gas content within.
“Aprotecol is an innovative product that will help to improve the quality of life of young patients across Italy affected by colic and bloating as well as their parents,” explained Noventure CEO Luciano Conde. “We firmly believe that partnering with Pierre Fabre, whose commitment to children’s healthcare is recognized worldwide, represents a great opportunity for Noventure to further disseminate its innovative barrier technology.”
The partnership represents part of Noventure’s wider business model which focuses on offering exclusive commercial rights for select geographic locations to each of its distribution partners.
Charles-Henri Bodin, General Manager of Pierre Fabre Pharma Italy, added: “Aprotecol is a great opportunity for Pierre Fabre to reinforce its position in paediatrics in Italy. Our teams are prepared and highly motivated to offer Italian paediatricians this innovative solution to treat their young patients.”
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Novogenia breaks ground on personalised healthcare campus
Novogenia AG has broken ground on a new headquarters and laboratory campus in Hallwang, Austria, …
